Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 254

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 254
---
 with this offering. In addition, we have agreed to issue to the representative of the underwriters or its designee an aggregate of 200,000 ordinary shares (or up to 230,000 ordinary shares if the underwriters’ over -allotmentoption is exercised in full), which we refer to herein as the “representative shares”, as part of representative compensation, which will be issued upon the consummation of this offering.

159 The underwriters propose to offer the units to the public at the initial public offering price set forth on the cover of this prospectus. In addition, the underwriters may offer some of the units to other securities dealers at such price less a concession of $0.05 per unit. If all of the units offered by us are not sold at the initial public offering price, the Representative may change the offering price and other selling terms by means of a supplement to this prospectus. We have also agreed to pay all expenses relating to the offering, including: (a) all filing fees and expenses relating to the registration of the securities with the SEC; (b) all fees and expenses relating to the listing of the securities on Nasdaq; (c) all fees associated with the review of the offering by FINRA, including legal fees and background checks of our principals; (d) all fees, expenses and disbursements relating to the registration, qualification or exemption of units offered under “blue sky” securities laws or the securities laws of foreign jurisdictions designated by the Representative, including the reasonable fees and expenses of the Representative’s blue sky counsel; (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of the units under the securities laws of such foreign jurisdictions; (f) the costs of mailing and printing the offering materials; (g) transfer and/or stamp taxes, if any, payable upon our transfer of the shares to the Representative; (h) the fees and expenses of our accountants; and (i) actual accountable expenses of the Representative, subject to a maximum amount of $100,000, which amount includes expenses for the Representative’s legal counsel and road show expenses. Previously, we paid an advance of $50,000 (the “Advance”) to EF Hutton LLC (the “Prior Underwriter”), the previous representative of underwriters, whose engagement was terminated on October 23, 2024, for their anticipated out -of -pocketexpenses; any advance will be returned to us to the extent the Prior Underwriter’s out -of